BNTX240920C95000
- 21.82
- -13.78-38.71%
BioNTech Newsroom
UBS Maintains BioNTech(BNTX.US) With Hold Rating, Raises Target Price to $131
UBS Maintains Neutral on BioNTech, Raises Price Target to $131
BioNTech Price Target Raised to $150.00/Share From $96.00 by Jefferies
A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $125 to $171
BioNTech Analyst Ratings
Jefferies Upgrades BioNTech SE (BNTX) to a Buy
Evercore ISI Sticks to Its Hold Rating for BioNTech SE (BNTX)
BioNTech Price Target Raised to $150.00/Share From $125.00 by B of A Securities
BioNTech Is Maintained at Buy by B of A Securities
BioNTech SE (BNTX) Gets a Hold From TD Cowen
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
BofA Securities Maintains BioNTech(BNTX.US) With Buy Rating, Raises Target Price to $150
J.P. Morgan Upgrades BioNTech(BNTX.US) to Hold Rating, Announces Target Price $125
Buy Rating Affirmed for BioNTech SE Following Promising Clinical Trial Results in Oncology
BioNTech Is Maintained at Hold by Jefferies
BioNTech Analyst Ratings
CCORF Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $171
Promising BNT327 Data Bolsters BioNTech's Buy Rating, With a Target of $171
J.P. Morgan Sticks to Its Sell Rating for BioNTech SE (BNTX)
Morgan Stanley Maintains BioNTech(BNTX.US) With Hold Rating, Maintains Target Price $93